Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
JTO Clinical and Research Reports（2022）
摘要
The updated results further confirm the favorable benefit and acceptable safety of savolitinib in Chinese patients with ex14-positive NSCLC.
更多查看译文
关键词
Savolitinib,Non–small cell lung cancer,METex14 skipping mutations,Pulmonary sarcomatoid carcinoma,MET tyrosine kinase inhibitors
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要